Why BI-RADS 4 Is Not a Breast Cancer Diagnosis

Seeing “BI-RADS 4” on your breast imaging report can feel like reading a cancer result. It is not one. BI-RADS is a standardized language for describing imaging findings, assigning a level of concern, and recommending the next action. Category 4 means suspicious enough to justify tissue diagnosis.

The current American College of Radiology BI-RADS system covers mammography, ultrasound, breast MRI, and contrast-enhanced mammography. Its purpose is consistent communication and management, not replacing pathology.

Category 4 spans an unusually broad probability range: greater than 2 percent but less than 95 percent likelihood of malignancy: a category 4A finding sits near the lower end; a 4C finding sits near the upper end. Both usually lead to biopsy because imaging alone has not provided a definitive answer.

What BI-RADS is designed to do#

BI-RADS stands for Breast Imaging Reporting and Data System. The ACR created it to standardize terminology, report structure, final assessment, management recommendations, audit, and outcome tracking.

The current BI-RADS v2025 Manual, released in late 2025, extends the prior atlas and updates terminology across mammography, ultrasound, MRI, contrast-enhanced mammography, and auditing. Patients may still encounter references to older editions in reports or online materials, but the basic distinction between imaging assessment and pathology remains central.

A radiologist interprets the shape, margin, density, calcification pattern, enhancement, distribution, vascularity, and other modality-specific features. The final category communicates what should happen next. It does not name the microscopic disease. The report may assign categories to more than one finding or breast, so if you read one number without the lesion description, laterality, location, comparison, and recommendation, it is easy to come away confused.

How categories 0 through 6 differ#

Category 0 means the evaluation is incomplete and more imaging or prior examinations are needed, and it is common after screening mammography callbacks and is not a final statement of malignancy probability.

Category 1 is negative. Category 2 describes benign findings. Both generally return you to the appropriate routine screening pathway.

Category 3 means probably benign, conventionally no more than a 2 percent probability of malignancy. Short-interval imaging is usually recommended to establish stability rather than immediate biopsy, provided the finding and clinical context fit category 3 criteria.

Category 4 is suspicious and generally recommends tissue diagnosis. Category 5 is highly suggestive of malignancy, with at least 95 percent probability, and also requires biopsy. Even category 5 is not a final pathology diagnosis because treatment planning depends on tissue type, invasion, grade, receptor results, and imaging-pathology agreement. Category 6 is used after biopsy has already proved malignancy. It is the category that explicitly reflects a known tissue diagnosis being evaluated by imaging.

Why category 4 is so broad#

Imaging findings often sit between “probably benign” and “classic for malignancy.” A new group of calcifications may not have the most ominous pattern but cannot safely be called benign; a solid mass may have mostly reassuring features with one suspicious margin. MRI may show nonmass enhancement that exceeds a follow-up threshold without having a specific pathology.

Category 4 creates a common action threshold for these uncertain but actionable findings. The broad range acknowledges that some lesions barely cross that threshold while others nearly meet category 5.

The category is not meant to predict your result with exact precision. The stated range comes from populations and standardized assessment. Your own probability also reflects age, symptoms, prior cancer, family and genetic risk, breast density, modality, lesion type, and the quality of prior comparison. The radiologist's job is to classify the imaging finding; the pathology laboratory's job is to examine the tissue that comes out. Those are different pieces of information, and you need both.

What 4A, 4B, and 4C communicate#

When a report provides a subcategory, conventional probability ranges are:

• BI-RADS 4A: low suspicion, greater than 2 percent to 10 percent.
• BI-RADS 4B: moderate suspicion, greater than 10 percent to 50 percent.
• BI-RADS 4C: high suspicion, greater than 50 percent to less than 95 percent.

These bands communicate concern and help with audit and pathology correlation. They are ranges, not a personalized percentage. A 4A label does not mean exactly 5 percent, and a 4C label does not prove cancer.

Subcategory usage can vary by modality and practice. Older research on breast MRI noted that the prior atlas did not formally require MRI subcategorization, while practices sometimes used it, though the current report and current BI-RADS manual are the appropriate sources for how a given modality is classified now.

If your report only says category 4, the ordering clinician or the breast imaging service can tell you whether a subcategory was assigned and what feature prompted biopsy. The absence of a subcategory does not invalidate the recommendation.

Why most 4A biopsies being benign is expected#

At a risk range just over 2 to 10 percent, roughly 90 percent or more of 4A findings can be benign in a well-calibrated system, which is not evidence that biopsy was unnecessary after the fact. The purpose of the threshold is to identify the smaller group with cancer when imaging cannot separate it reliably from benign mimics.

The alternative, short-interval follow-up, is appropriate for category 3 findings whose features and risk remain at or below the probably-benign threshold. Once concern exceeds that boundary, waiting can delay diagnosis for the minority with malignancy.

Biopsy recommendations can still be reviewed. Prior images may show long-term stability. A second breast radiologist may reclassify a finding after complete diagnostic views. Clinical circumstances may affect timing or method. Review is different from assuming the lower probability makes tissue unnecessary. The quality of the decision is judged from the evidence available when it was made, not solely from how the biopsy turned out.

How the biopsy method is selected#

The safest efficient method usually uses the modality that best and most consistently displays the target. An ultrasound-visible mass is often sampled with ultrasound-guided core needle biopsy. The radiologist can watch the needle in real time, and the procedure does not use ionizing radiation.

Calcifications or architectural distortion seen on mammography or tomosynthesis may require stereotactic or tomosynthesis-guided biopsy. The specimen may be radiographed to confirm that the target calcifications are present.

An abnormality seen only on contrast-enhanced MRI may need MRI-guided biopsy. Contrast-enhanced mammography findings can require a modality-specific route or a search for an ultrasound correlate.

The lesion's size, location, visibility, proximity to skin or implant, bleeding risk, patient position, and local resources affect method. Core needle biopsy is generally preferred over fine-needle aspiration for many solid breast lesions because tissue architecture and biomarkers may be needed.

What happens during image-guided core biopsy#

After confirming identity, target, side, medications, allergies, and consent, the team positions the breast and uses imaging to localize the lesion. Local anesthetic numbs your skin and the path the needle takes. A spring-loaded or vacuum-assisted device retrieves tissue samples.

A small marker clip is often placed at the sampled site. The clip helps future imaging identify the location if the lesion becomes less visible, if surgery is needed, or if pathology is benign and follow-up comparison matters. The marker is not a cancer treatment and generally does not trigger airport detectors.

Pressure reduces bleeding, and post-procedure images may document clip position. Bruising and soreness are common. Serious bleeding or infection is uncommon, but you should be given instructions for increasing swelling, uncontrolled bleeding, fever, drainage, severe pain, or other concerns. Pathology time varies, and when the result arrives it needs clinical and radiologic review rather than being interpreted only from a portal label.

Pathology can return several kinds of answer#

Malignant results include ductal carcinoma in situ and invasive cancers, among others. Additional tests may characterize hormone receptors, HER2, grade, and other features needed for treatment planning.

Benign diagnoses include cyst-related change, fibroadenoma, fat necrosis, fibrosis, or other noncancerous tissue. A benign label is reassuring only when it adequately explains the imaging target and the sampling was technically satisfactory.

Some results are called high-risk, borderline, or lesions of uncertain malignant potential. Examples can include atypical ductal hyperplasia, certain papillary lesions, lobular neoplasia, radial scar or complex sclerosing lesion, and phyllodes-type findings. Management depends on the exact lesion, sampling method, imaging features, concordance, extent, and current guidance. It may involve imaging follow-up, larger sampling, or surgical excision.

A nondiagnostic or insufficient sample also does not close the case. The correct next action follows the original concern and why the tissue was inadequate.

Imaging-pathology concordance is the safety check#

Concordance asks whether the pathology result plausibly explains what the radiologist saw. A benign concordant result means the tissue diagnosis fits the imaging appearance and the correct target appears to have been sampled.

Discordance means the pieces do not fit. A spiculated mass followed by nonspecific benign tissue may represent sampling error. Suspicious calcifications may be absent from the specimen. A marker may not sit at the intended site.

The American Society of Breast Surgeons resource states that concordance assessment should occur after percutaneous breast biopsy. A benign discordant result needs further tissue, often repeat image-guided biopsy with a suitable technique or surgical excision. So “the biopsy was benign” is not the final sentence by itself. What you want to hear next is whether the result is concordant, and what the follow-up recommendation is.

Timing and follow-up closure#

A category 4 recommendation should have an owner and a time-bound plan. Delays can arise from insurance authorization, missing referrals, travel, pregnancy, anticoagulation questions, or communication failures. The breast imaging service and referring team should define who tracks completion.

The urgency is not identical for every subcategory or clinical setting, but an open-ended delay is not appropriate. New symptoms such as a growing palpable mass, skin retraction, bloody nipple discharge, or inflammatory change can increase concern and should be communicated.

After biopsy, the team should document pathology, concordance, whether more tissue is needed, and the next imaging interval. If your care moves between systems, you may need copies of the reports, the pathology, and the images rather than only a verbal summary.

Common interpretation mistakes#

One mistake is reading 4A as almost certainly cancer. Its range is low suspicion, and benign pathology is expected in most cases. Another is reading 4C as already proved. The probability is high, but pathology still decides diagnosis and guides treatment.

A third mistake is confusing a screening callback, often category 0, with category 4. Additional diagnostic views frequently resolve a callback without biopsy.

A fourth is assuming that a benign pathology word ends follow-up. Concordance must be stated. A fifth is using internet averages to calculate a personal result without accounting for the report's modality, lesion, history, and current edition. What you should be told, before any of it starts, is the exact target, the category and subcategory, the proposed biopsy method, the expected timeline, and what will happen for malignant, benign concordant, high-risk, or discordant results.

References#

1. American College of Radiology BI-RADS current release
2. ACR overview of the BI-RADS v2025 manual
3. RadiologyInfo guide to reading a breast imaging report
4. RadiologyInfo guide to image-guided breast biopsy
5. American Society of Breast Surgeons guide to high-risk lesions and concordance
6. Study of BI-RADS category 4 subcategory ranges
7. ACR breast ultrasound guided procedure practice parameter